Aptinyx crashes after nerve pain drug failure, BMO Capital halves PT
U.S. STOCKS ON THE MOVE-Macy's, Conduent, Pfizer
U.S. STOCKS ON THE MOVE-Netflix, Rite Aid, TotalEnergies SE
U.S. STOCKS ON THE MOVE-CDK Global, Sprinklr, Biophytis
Aptinyx plunges after pain drug fails mid-stage trial
NASDAQ RESUMED AT 07:30 AM
Brief: Aptinyx Reports Results From Phase 2B Study Of Nyx-2925 In Painful Diabetic Peripheral Neuropathy
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Brief: Aptinyx Inc Files For Mixed Shelf Of Up To $200 Million
Wedbush cuts PT on Aptinyx on lower net cash
Aptinyx Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aptinyx Reports Fourth Quarter And Full Year 2021 Results
Aptinyx Inc expected to post a loss of 35cents a share - Earnings Preview
Brief: Aptinyx Completes Enrollment In Phase 2B Study Of Nyx-2925 In Fibromyalgia
Brief: Aptinyx Inc - Ended Q4 Of 2021 With About $106 Million In Cash And Cash Equivalents (Unaudited)
U.S. RESEARCH ROUNDUP-Boston Beer Company, Extra Space Storage, Starbucks
Brief: Aptinyx Initiates Phase 2B Study Of NYX-783 In Patients With Post-Traumatic Stress Disorder
Aptinyx Inc reports results for the quarter ended in September - Earnings Summary
Brief: Aptinyx Reports Third Quarter 2021 Financial Results And Recent Highlights